tiprankstipranks
Advertisement
Advertisement
Abbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication
PremiumCompany AnnouncementsAbbisko’s TGCT Drug Pimicotinib Clears Key Global Milestone With Lancet Phase 3 Publication
28d ago
Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial
Premium
Company Announcements
Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial
1M ago
Abbisko Chairman Boosts Stake, Signalling Confidence While Maintaining Public Float
Premium
Company Announcements
Abbisko Chairman Boosts Stake, Signalling Confidence While Maintaining Public Float
1M ago
Abbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data
PremiumCompany AnnouncementsAbbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data
3M ago
Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141
Premium
Company Announcements
Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141
3M ago
Abbisko Wins First Global Approval for TGCT Drug Pimicotinib in China
Premium
Company Announcements
Abbisko Wins First Global Approval for TGCT Drug Pimicotinib in China
3M ago
Abbisko Therapeutics Advances Phase II Study for NSCLC Treatment
PremiumCompany AnnouncementsAbbisko Therapeutics Advances Phase II Study for NSCLC Treatment
5M ago
Abbisko Therapeutics Unveils Promising Preclinical Cancer Drug Findings
Premium
Company Announcements
Abbisko Therapeutics Unveils Promising Preclinical Cancer Drug Findings
5M ago
Abbisko’s Pimicotinib Shows Promising Results in Phase III TGCT Trial
Premium
Company Announcements
Abbisko’s Pimicotinib Shows Promising Results in Phase III TGCT Trial
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100